Thrombopoietin to replace megakaryocyte-derived growth factor: impact on stem and progenitor cells during ex vivo expansion of CD34+ cells mobilized in peripheral blood.

MLA

Duchez, Pascale, et al. “Thrombopoietin to Replace Megakaryocyte-Derived Growth Factor: Impact on Stem and Progenitor Cells during Ex Vivo Expansion of CD34+ Cells Mobilized in Peripheral Blood.” Transfusion, vol. 51, no. 2, Feb. 2011, pp. 313–18. EBSCOhost, https://doi.org/10.1111/j.1537-2995.2010.02860.x.

APA

Duchez, P., Chevaleyre, J., Vlaski, M., Dazey, B., Bijou, F., Lafarge, X., Milpied, N., Boiron, J.-M., & Ivanovic, Z. (2011). Thrombopoietin to replace megakaryocyte-derived growth factor: impact on stem and progenitor cells during ex vivo expansion of CD34+ cells mobilized in peripheral blood. Transfusion, 51(2), 313–318. https://doi.org/10.1111/j.1537-2995.2010.02860.x

Chicago

Duchez, Pascale, Jean Chevaleyre, Marija Vlaski, Bernard Dazey, Fontanet Bijou, Xavier Lafarge, Noël Milpied, Jean-Michel Boiron, and Zoran Ivanovic. 2011. “Thrombopoietin to Replace Megakaryocyte-Derived Growth Factor: Impact on Stem and Progenitor Cells during Ex Vivo Expansion of CD34+ Cells Mobilized in Peripheral Blood.” Transfusion 51 (2): 313–18. doi:10.1111/j.1537-2995.2010.02860.x.